Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion type Assertion NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_head.
- NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion description "[Several clinical trials have showed that patients with metastatic colorectal cancer (mCRC) who present tumour-promoting mutations in signalling pathways involving the epidermal growth factor receptor (EGFR), which includes activating K-RAS mutations, do not respond to anti-EGFR drugs such as panitumumab and cetuximab.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_provenance.
- NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion evidence source_evidence_literature NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_provenance.
- NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion SIO_000772 24793846 NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_provenance.
- NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion wasDerivedFrom befree-2016 NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_provenance.
- NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_assertion wasGeneratedBy ECO_0000203 NP1179156.RAKElqbvABbga5S_7wlxgqnQ9iJwTmCfNsoniI1iKaqXw130_provenance.